Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to ...
The agreement with NanoVation marks the second big recent deal that a B.C. biotech startup has struck with the Danish ...
ME Therapeutics to begin testing of first mRNA formulations from NanoVation Therapeutics collaboration: Vancouver, British Columbia Friday, September 20, 2024, 14:00 Hrs [IST] ME ...
NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with ...
Canada’s NanoVation Therapeutics has partnered with Novo Nordisk to advance genetic medicines for cardiometabolic and rare ...
NanoVation Therapeutics partners with Novo Nordisk to develop genetic medicines for cardiometabolic and rare diseases, ...
GlobalData on MSN23h
Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseasesNanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...
The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.
The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...
Debanjana Chatterjee, an analyst from JonesTrading, has initiated a new Buy rating on Intellia Therapeutics (NTLA). Debanjana Chatterjee’s rating is based on the potential of Intellia ...
ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback